HIV associated nephropathy future or investigational therapies: Difference between revisions
m Changes made per Mahshid's request |
No edit summary |
||
| Line 2: | Line 2: | ||
{{HIV associated nephropathy}} | {{HIV associated nephropathy}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
== Overview == | |||
== Future or Investigational Therapies == | |||
* more research is needed to determine novel therapies such as molecular targeting to prevent or delay progression to ESRD. | |||
* The initiation of HIV-positive donor to HIV-positive recipient kidney transplantation, in South Africa and now available in the United States, offers great promise to patients who previously may not have survived to transplantation, though long-term outcomes remain unclear as well as the lack of data on estimated risk of recurrent disease. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 06:29, 26 June 2020
|
HIV associated nephropathy Microchapters |
|
Differentiating HIV associated nephropathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
HIV associated nephropathy future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of HIV associated nephropathy future or investigational therapies |
|
FDA on HIV associated nephropathy future or investigational therapies |
|
CDC on HIV associated nephropathy future or investigational therapies |
|
HIV associated nephropathy future or investigational therapies in the news |
|
Blogs on HIV associated nephropathy future or investigational therapies |
|
Risk calculators and risk factors for HIV associated nephropathy future or investigational therapies |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Future or Investigational Therapies
- more research is needed to determine novel therapies such as molecular targeting to prevent or delay progression to ESRD.
- The initiation of HIV-positive donor to HIV-positive recipient kidney transplantation, in South Africa and now available in the United States, offers great promise to patients who previously may not have survived to transplantation, though long-term outcomes remain unclear as well as the lack of data on estimated risk of recurrent disease.